source
- Sanofi pauses Phase 2 bronchiectasis study of SAR445399 amid new CEO’s portfolio reviewSanofi has halted a Phase 2 trial of its investigational antibody SAR445399 in non‑cystic fibrosis bronchiectasis. The pause was attributed to strategic business reasons linked to an internal portf…
- Vedanta Biosciences secures $60 million to complete Phase 3 trial of C. difficile microbiome therapyVedanta Biosciences, a Cambridge, MA biotech focused on microbiome therapeutics, announced it has raised $60 million in new financing. The capital will be used to advance its lead candidate target…